Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 16/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21776892 | 0.76 | NOTUM (0.61) | NOTUMKDM4EALDH1A1MAPT | |
| SCHEMBL17694561 | 0.68 | NOTUM (0.78) | NOTUMKDM4ELMNAALDH1A1HPGD | |
| SCHEMBL720137 | 0.68 | NOTUM (0.50) | NOTUMALDH1A1MAPT | |
| SCHEMBL18429566 | 0.67 | NOTUM (0.50) | NOTUM | |
| SCHEMBL2631356 | 0.66 | NOTUM (0.49) | NOTUM | |
| SCHEMBL16178963 | 0.66 | NOTUM (0.49) | NOTUMKDM4ELMNAALDH1A1MAPK1 | |
| SCHEMBL16258580 | 0.66 | NOTUM (0.63) | NOTUMKDM4ELMNAALDH1A1HPGD | |
| SCHEMBL11652205 | 0.66 | NOTUM (0.53) | NOTUMKDM4ELMNAALDH1A1HPGD | |
| SCHEMBL8982307 | 0.66 | NOTUM (0.49) | NOTUMKDM4EALDH1A1MAPT | |
| SCHEMBL3421790 | 0.66 | NOTUM (0.49) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885KDM4E 3907/4885LMNA 2507/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885KDM4E 4149/4885LMNA 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.